196 related articles for article (PubMed ID: 21349401)
1. Cardiovascular events in patients with fabry disease natural history data from the fabry registry.
Patel MR; Cecchi F; Cizmarik M; Kantola I; Linhart A; Nicholls K; Strotmann J; Tallaj J; Tran TC; West ML; Beitner-Johnson D; Abiose A
J Am Coll Cardiol; 2011 Mar; 57(9):1093-9. PubMed ID: 21349401
[TBL] [Abstract][Full Text] [Related]
2. End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry.
Ortiz A; Cianciaruso B; Cizmarik M; Germain DP; Mignani R; Oliveira JP; Villalobos J; Vujkovac B; Waldek S; Wanner C; Warnock DG
Nephrol Dial Transplant; 2010 Mar; 25(3):769-75. PubMed ID: 19846394
[TBL] [Abstract][Full Text] [Related]
3. Evaluating enzyme replacement therapy in fabry disease.
Koskenvuo JW; Kantola IM
Arch Intern Med; 2010 Mar; 170(6):573-4; author reply 574. PubMed ID: 20308647
[No Abstract] [Full Text] [Related]
4. Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry.
Sims K; Politei J; Banikazemi M; Lee P
Stroke; 2009 Mar; 40(3):788-94. PubMed ID: 19150871
[TBL] [Abstract][Full Text] [Related]
5. Dialysis and transplantation in Fabry disease: indications for enzyme replacement therapy.
Mignani R; Feriozzi S; Schaefer RM; Breunig F; Oliveira JP; Ruggenenti P; Sunder-Plassmann G
Clin J Am Soc Nephrol; 2010 Feb; 5(2):379-85. PubMed ID: 20056752
[TBL] [Abstract][Full Text] [Related]
6. Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy.
Ortiz A; Oliveira JP; Waldek S; Warnock DG; Cianciaruso B; Wanner C;
Nephrol Dial Transplant; 2008 May; 23(5):1600-7. PubMed ID: 18175781
[TBL] [Abstract][Full Text] [Related]
7. Fabry disease in Argentina: an evaluation of patients enrolled in the Fabry Registry.
Politei JM; Cabrera G; Amartino H; Valdez R; Masllorens F; Ripeau D; Antongiovanni N; Soliani A; Luna P; Cedrolla M; Fernandez S; Fainboim A
Int J Clin Pract; 2013 Jan; 67(1):66-72. PubMed ID: 23241050
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular testing in Fabry disease: exercise capacity reduction, chronotropic incompetence and improved anaerobic threshold after enzyme replacement.
Lobo T; Morgan J; Bjorksten A; Nicholls K; Grigg L; Centra E; Becker G
Intern Med J; 2008 Jun; 38(6):407-14. PubMed ID: 18613897
[TBL] [Abstract][Full Text] [Related]
9. Impact of measures to enhance the value of observational surveys in rare diseases: the Fabry Outcome Survey (FOS).
Clarke JT; Giugliani R; Sunder-Plassmann G; Elliott PM; Pintos-Morell G; Hernberg-Ståhl E; Malmenäs M; Beck M;
Value Health; 2011; 14(6):862-6. PubMed ID: 21914507
[TBL] [Abstract][Full Text] [Related]
10. Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis.
Turajane T; Wongbunnak R; Patcharatrakul T; Ratansumawong K; Poigampetch Y; Songpatanasilp T
J Med Assoc Thai; 2009 Dec; 92 Suppl 6():S19-26. PubMed ID: 20128070
[TBL] [Abstract][Full Text] [Related]
11. Hearing loss in Fabry disease: data from the Fabry Outcome Survey.
Hegemann S; Hajioff D; Conti G; Beck M; Sunder-Plassmann G; Widmer U; Mehta A; Keilmann A
Eur J Clin Invest; 2006 Sep; 36(9):654-62. PubMed ID: 16919049
[TBL] [Abstract][Full Text] [Related]
12. Cardiac challenges in patients with Fabry disease.
Weidemann F; Linhart A; Monserrat L; Strotmann J
Int J Cardiol; 2010 May; 141(1):3-10. PubMed ID: 19720409
[TBL] [Abstract][Full Text] [Related]
13. Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment.
Weidemann F; Niemann M; Breunig F; Herrmann S; Beer M; Störk S; Voelker W; Ertl G; Wanner C; Strotmann J
Circulation; 2009 Feb; 119(4):524-9. PubMed ID: 19153271
[TBL] [Abstract][Full Text] [Related]
14. [Cardiological follow-up in patients with Fabry disease].
Pieruzzi F; Pieroni M; Chimenti C; Frustaci A; Sarais C; Cecchi F;
G Ital Cardiol (Rome); 2010; 11(7-8):566-72. PubMed ID: 21033333
[TBL] [Abstract][Full Text] [Related]
15. Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults.
Ortiz A; Oliveira JP; Wanner C; Brenner BM; Waldek S; Warnock DG
Nat Clin Pract Nephrol; 2008 Jun; 4(6):327-36. PubMed ID: 18431378
[TBL] [Abstract][Full Text] [Related]
16. Enzyme replacement therapy and Fabry nephropathy.
Warnock DG; Daina E; Remuzzi G; West M
Clin J Am Soc Nephrol; 2010 Feb; 5(2):371-8. PubMed ID: 20007680
[TBL] [Abstract][Full Text] [Related]
17. Fabry disease with aortic regurgitation.
Choi S; Seo H; Park M; Kim J; Hwang S; Kwon K; Her K; Won Y
Ann Thorac Surg; 2009 Feb; 87(2):625-8. PubMed ID: 19161799
[TBL] [Abstract][Full Text] [Related]
18. Hypertension and diabetes mellitus are associated with cardiovascular events in the elderly without cardiovascular disease. Results of a 15-year follow-up in a Mediterranean population.
Noto D; Cefalù AB; Barbagallo CM; Sapienza M; Cavera G; Nardi I; Pagano M; Vivona N; Notarbartolo A; Averna MR
Nutr Metab Cardiovasc Dis; 2009 Jun; 19(5):321-6. PubMed ID: 18571394
[TBL] [Abstract][Full Text] [Related]
19. How does the prognosis of diabetes compare with that of established vascular disease? Insights from the Canadian Vascular Protection (VP) Registry.
Hackam DG; Tan MK; Honos GN; Leiter LA; Langer A; Goodman SG;
Am Heart J; 2004 Dec; 148(6):1028-33. PubMed ID: 15632889
[TBL] [Abstract][Full Text] [Related]
20. [Fabry disease in Italy: first epidemiologic and collaborative study].
Ricci R; Castorina M; Di Lillo M; Antuzzi D; Frustaci A; Parini R; Menni F; Furlan F; Burlina A; Burlina A; Catuogno S; Gabrielli O; Burattini I; Borsini W; Buchner S; Ferriozzi S; Spisni C; De Vito R; Di Rocco M; Aricò M; Pistone G; Bongiorno AM; Morrone A; Cavicchi C; Zammarchi E
Ann Ital Med Int; 2004; 19(4):269-75. PubMed ID: 15678707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]